List of Excipients in Branded Drug LEVOTHYROXINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-3281	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-3281	MAGNESIUM STEARATE
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-3281	SILICON DIOXIDE

Generic Drugs Containing LEVOTHYROXINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	BUTYLATED HYDROXYANISOLE
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	CROSPOVIDONE

What are the Most Frequently-Used Excipients in LEVOTHYROXINE?

# Of NDCs	Excipient

Levothyroxine Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: November 7, 2026

Levothyroxine is a mature active pharmaceutical ingredient with substantial formulation-driven commercial opportunity. The molecule itself is off-patent, but levothyroxine products remain sensitive to excipient selection, manufacturing controls, dissolution behavior, food effects, stability, and dose reproducibility. The strongest opportunities are low-excipient oral solutions, softgel capsules, allergen- and intolerance-focused tablets, and manufacturing platforms that reduce potency drift across the product shelf life.

What excipient strategy is most important for levothyroxine products?

The primary excipient objective is consistent delivery of a narrow therapeutic index drug at microgram dose strengths. Levothyroxine products must maintain dose uniformity and bioavailability across strengths, lots, storage conditions, and patients.

Levothyroxine sodium is chemically sensitive and is administered in very small quantities. A typical tablet may contain 25 to 300 micrograms of active ingredient, creating a high ratio of excipient mass to drug substance. Small changes in blending, compression, particle size, moisture, excipient grade, or dissolution can materially affect dose performance.

Formulation objective	Excipient or process lever	Commercial relevance
Dose uniformity	Ordered mixing, geometric dilution, low-dose premixes, controlled particle size	Reduces potency variability
Chemical stability	Low-moisture excipients, moisture-barrier packaging, controlled humidity	Protects shelf life
Rapid and consistent dissolution	Disintegrants, surfactants, soluble excipients, optimized compression	Supports predictable exposure
Reduced food interaction	Softgel or liquid delivery, lower dependence on tablet disintegration	Targets patients with variable absorption
Intolerance reduction	Removal of lactose, gluten-related excipients, dyes, sugars, or gelatin	Supports differentiated positioning
Manufacturing robustness	Direct compression or validated granulation platform	Reduces batch failure and scale-up risk
Pediatric administration	Oral solution, measured dosing device, palatable excipient system	Expands convenience and adherence

FDA treats levothyroxine as a narrow therapeutic index product. The agency has emphasized potency, stability, bioequivalence, and consistent manufacturing for generic and branded levothyroxine products. Product switching can require clinical monitoring because small exposure changes can affect thyroid-stimulating hormone levels.[1]

Which excipients are used in major levothyroxine formulations?

The market includes conventional tablets, softgel capsules, and oral solutions. Each dosage form uses a different excipient strategy.

Conventional tablets

Common tablet excipients include lactose, sucrose, microcrystalline cellulose, povidone, croscarmellose sodium, sodium starch glycolate, magnesium stearate, talc, calcium sulfate, starch, and colorants. The exact composition varies by manufacturer and strength.

Synthroid tablets have historically used a multi-excipient system that includes lactose monohydrate, acacia, confectioner's sugar, povidone, talc, magnesium stearate, and color additives, with strength-specific colorants. Levoxyl uses a different formulation architecture that includes calcium sulfate, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, talc, and strength-specific colorants. FDA labeling should control for current composition because inactive ingredients may vary across presentations and manufacturing changes.[2,3]

Tablet excipient systems offer low cost and high manufacturing throughput. Their main technical risks are:

• Sensitivity to moisture and storage conditions.
• Inconsistent disintegration or dissolution.
• Lubricant overmixing, particularly with magnesium stearate.
• Segregation at microgram drug loads.
• Variability caused by particle-size differences.
• Patient concerns involving lactose, dyes, sugar, or gluten-containing processing aids.

Softgel capsules

Tirosint is a liquid-filled softgel formulation. Its labeled inactive ingredients include gelatin, glycerin, and water.[4] The product avoids many excipients used in conventional tablets and does not depend on tablet compression or disintegration.

Softgel technology can create a differentiated product with:

• A limited inactive-ingredient profile.
• Reduced dependence on tablet disintegration.
• A potential positioning advantage for patients with excipient intolerance.
• A distinct manufacturing barrier involving fill uniformity, encapsulation, shell integrity, and stability.
• Higher cost than conventional tablets.

The principal weakness is the use of gelatin, which creates religious, dietary, and animal-origin restrictions. A plant-based or non-gelatin capsule shell could create a differentiated product, but the alternative shell must preserve oxygen and moisture control, mechanical strength, dissolution, and long-term stability.

Oral solutions

Tirosint-SOL is an oral solution containing levothyroxine sodium with glycerol and water listed as inactive ingredients.[5] The formulation reduces tablet-related variables and can support pediatric, geriatric, dysphagia, and dose-titration use cases.

The commercial tradeoffs include:

• Higher packaging and filling costs.
• Potential dosing-device requirements.
• Container-closure compatibility testing.
• Greater sensitivity to microbial control and preservative strategy.
• Transport and storage requirements.
• Risk of dose loss from residual liquid in the container or device.

A preservative-free, single-dose oral solution could be attractive for patients with excipient sensitivity. Multi-dose bottles may lower cost but introduce microbial, dosing, and in-use stability challenges.

What formulation characteristics create commercial opportunities?

The largest commercial opportunities are linked to clinically meaningful administration problems rather than simple excipient substitution.

Excipient-minimal products

A product containing only a small number of inactive ingredients can target patients who report intolerance to lactose, dyes, sugars, or tablet binders. The opportunity is strongest when supported by clear labeling and a reliable supply chain.

An excipient-minimal strategy should avoid overstating clinical benefit. Removing an excipient does not automatically improve thyroid control. The commercial value lies in patient selection, adherence, tolerability, and reduced switching risk.

Gluten- and lactose-conscious products

Patients with celiac disease, gluten sensitivity, or lactose intolerance may prefer products with a clearly documented excipient profile. A manufacturer can differentiate through:

• Verified gluten-free manufacturing controls.
• Lactose-free tablets.
• Transparent strength-specific inactive-ingredient labeling.
• Dedicated packaging and supply-chain controls.
• Pharmacist and endocrinology education.

The product label must support the claim. A broad "free from" statement creates regulatory and supply-chain obligations.

Pediatric and dysphagia formulations

Oral solutions offer the clearest route to pediatric and swallowing-related opportunities. A commercial product can compete through calibrated oral syringes, unit-dose packaging, low extractables, and stable concentration across the labeled shelf life.

Taste is a technical issue. Sweeteners and flavors may improve acceptance but add excipient complexity and can affect stability, microbial control, and patient preference. A neutral-taste formulation with a small dosing volume may be more defensible than a heavily flavored product.

Stable products for variable storage conditions

Levothyroxine supply has historically been exposed to potency concerns associated with heat, humidity, light, and packaging. Moisture-barrier blisters, high-barrier bottles, desiccants, and improved secondary packaging can create value even without a new active ingredient.

The opportunity is especially relevant in markets with:

• High ambient temperature.
• High humidity.
• Long distribution routes.
• Limited pharmacy storage control.
• Frequent patient transport of medication.

Dose-flexibility platforms

A liquid formulation can support more flexible dose titration than fixed-strength tablets. This can be valuable during pregnancy, pediatric treatment, thyroid cancer suppression therapy, and post-thyroidectomy titration.

Commercial differentiation can include:

• Smaller dosing increments.
• Unit-dose ampoules.
• Metered oral dispensers.
• Formulations compatible with feeding tubes.
• Reduced tablet splitting.

How do levothyroxine formulations compare commercially?

Product type	Typical excipient complexity	Main advantage	Main limitation	Commercial position
Generic tablet	Moderate to high	Lowest cost and broad availability	More formulation variables	Volume and payer-driven
Branded tablet	Moderate to high	Established prescriber recognition	Generic substitution pressure	Brand continuity
Softgel capsule	Low to moderate	Reduced tablet-related variability	Higher cost; gelatin shell	Premium differentiation
Oral solution	Low	Flexible dosing and swallowing benefit	Packaging and stability cost	Specialty and convenience
Single-dose liquid	Low	Hygiene and dosing control	Higher unit cost	Pediatric, institutional, specialty

Synthroid remains the major branded tablet reference product in the United States. Generic levothyroxine tablets compete primarily on price and formulary access. Tirosint and Tirosint-SOL compete through dosage-form differentiation rather than active-ingredient novelty.[2,4,5]

What patents protect levothyroxine formulations?

The active pharmaceutical ingredient, levothyroxine, is long off-patent. The relevant intellectual-property value is concentrated in formulation, dosage form, manufacturing process, packaging, and brand assets.

Potentially protectable categories include:

1. Liquid-filled softgel compositions.
2. Oral solution formulations with defined solvent or excipient systems.
3. Specific concentration and dosing formats.
4. Container-closure systems that preserve potency.
5. Manufacturing processes for low-dose content uniformity.
6. Stability-improving excipient combinations.
7. Device and packaging systems.
8. Method-of-use claims directed to administration or patient subgroups.

Formulation patents require careful claim construction. A patent covering a specific excipient combination may not block a conventional tablet using different excipients. A process patent may be avoidable through an alternative manufacturing route. A dosage-form patent may have stronger commercial value when the dosage form is difficult to replicate at scale.

Orange Book and listed-patent considerations

FDA Orange Book analysis is product-specific. The relevant questions are:

• Whether the reference product has active listed patents.
• Whether those patents cover the dosage form, formulation, method of use, or device.
• Whether an ANDA applicant must certify under Paragraph I, II, III, or IV.
• Whether pediatric exclusivity or other regulatory exclusivity attaches.
• Whether the patent is enforceable and commercially relevant at the expected launch date.

For mature levothyroxine products, generic entry risk generally centers on formulation substitution, manufacturing consistency, and regulatory review rather than basic active-ingredient patent protection. A Paragraph IV certification could still arise against an unexpired listed formulation or method-of-use patent, but the commercial impact depends on patent scope and the applicant's ability to design around the claims.

When does levothyroxine lose exclusivity?

Levothyroxine has already lost active-ingredient and basic composition-of-matter exclusivity. Market exclusivity is therefore product-specific.

Exclusivity category	Levothyroxine status
Active-ingredient patent	Expired
Conventional tablet competition	Established
Generic ANDA pathway	Available for eligible reference products
Softgel formulation protection	May depend on formulation and patent status
Oral-solution protection	May depend on formulation, device, and listed patents
Brand trademark protection	Remains separate from patent exclusivity
Trade-secret protection	Can remain important for manufacturing and quality control

Brand products may retain revenue after patent expiry through prescriber familiarity, supply reliability, patient continuity, dosage-form differentiation, and payer positioning. Patent expiry does not eliminate these commercial defenses, but it increases substitution pressure.

Are Paragraph IV challenges a material risk for levothyroxine?

Paragraph IV risk is material when a branded formulation has unexpired Orange Book-listed patents and the product has meaningful sales. The main challenge theories may include:

• Non-infringement based on a different excipient system.
• Invalidity based on obviousness or lack of adequate written description.
• Lack of infringement because the ANDA product does not practice a claimed process.
• Patent expiration before commercial launch.
• Regulatory non-applicability of a method-of-use patent.

The strongest defense for a formulation patent is usually a narrow but technically difficult claim tied to a reproducible product attribute or manufacturing requirement. Broad claims covering ordinary excipients are more exposed to invalidity and design-around arguments.

Settlement agreements can delay generic entry, permit an authorized generic, provide a license, or establish a date certain for launch. Any analysis must distinguish a patent-litigation settlement from a supply or licensing agreement. These instruments can have different antitrust and revenue consequences.

Which companies are competing in levothyroxine excipients and dosage forms?

The leading commercial groups include:

• AbbVie, associated with Synthroid.
• Lannett and other generic manufacturers that have commercialized levothyroxine tablets.
• IBSA, associated with Tirosint and Tirosint-SOL in the United States.
• Viatris, Teva, and other generic pharmaceutical companies participating in thyroid replacement markets, depending on product and jurisdiction.
• Regional manufacturers supplying tablets, capsules, and oral solutions outside the United States.

Competition is not uniform across countries. Regulatory approvals, reference products, substitution rules, local patent filings, and reimbursement policies determine the practical market position.

What manufacturing and IP barriers affect levothyroxine products?

The principal barrier is not synthesis of levothyroxine. It is reproducible finished-dose manufacturing.

Key barriers include:

• Microgram-scale content uniformity.
• Narrow potency specifications.
• Low-dose blending and segregation control.
• Moisture and temperature management.
• Stability-indicating analytical methods.
• Consistent dissolution across strengths.
• Softgel encapsulation and shell control.
• Sterile or low-bioburden liquid processing where applicable.
• Container-closure performance.
• Demonstration of bioequivalence.
• Change-control management across excipient suppliers.

A manufacturer with a reliable low-dose platform can have an advantage even without broad patent protection. Process capability, validated suppliers, analytical methods, and regulatory history can function as practical barriers to entry.

How does levothyroxine compare with other narrow therapeutic index drugs?

Levothyroxine has a particularly strong formulation sensitivity because:

• Doses are very small.
• Clinical titration depends on laboratory measurements.
• Patients often use the product chronically.
• Food, supplements, gastric conditions, and co-administered medicines can affect absorption.
• Small exposure changes can produce clinically relevant TSH changes.
• Switching among products can trigger monitoring and dose adjustment.

Compared with many conventional oral drugs, the excipient system has a larger role in commercial positioning. The product is not differentiated by new pharmacology. It is differentiated by dose consistency, administration convenience, tolerability, and supply reliability.

What generic launch scenarios exist for levothyroxine?

Low-cost tablet launch

This is the most likely competitive model for a conventional product. The entrant competes on price, wholesaler access, pharmacy substitution, and supply continuity. Margin pressure is high.

Premium softgel launch

A softgel entrant must match stability, dissolution, dose uniformity, and encapsulation performance. It can target patients who experience intolerance or inconsistent control with tablets, but reimbursement may limit uptake.

Oral-solution launch

An oral-solution entrant can target pediatric, geriatric, dysphagia, and dose-flexibility segments. The commercial opportunity depends on device usability, unit economics, and payer coverage.

Authorized-generic strategy

A branded manufacturer can license or supply a generic version to defend volume and capture lower-price demand. This approach can reduce third-party share while accelerating internal substitution.

Regional excipient differentiation

In markets where lactose, gelatin, dyes, or gluten-related concerns influence prescribing, a locally optimized formulation can capture niche demand without challenging the entire tablet market.

What is the revenue exposure to excipient and formulation competition?

Revenue exposure is highest where the branded product has:

• High prescription volume.
• Significant price premium over generic tablets.
• A large chronic-use population.
• Limited dosage-form differentiation.
• High pharmacy substitution rates.
• Few barriers to switching.

Revenue exposure is lower where the product has:

• A softgel or oral-solution platform.
• Strong patient continuity.
• Limited generic competition in the same dosage form.
• Device or packaging differentiation.
• Reliable supply during shortages.
• Formulation-specific patents or regulatory exclusivity.

The most defensible commercial strategy combines formulation differentiation with manufacturing reliability. Patent protection alone is less likely to sustain value for a mature thyroid replacement product if competitors can design around the claims.

Key Takeaways

• Levothyroxine's active ingredient is off-patent; formulation and manufacturing are the main competitive battlegrounds.
• Conventional tablets offer the lowest cost but have greater excipient and dissolution complexity.
• Softgels reduce tablet-related variables and support premium positioning, but gelatin and manufacturing cost limit reach.
• Oral solutions create opportunities in pediatrics, dysphagia, flexible dosing, and excipient minimization.
• The strongest technical barriers involve microgram-scale content uniformity, potency stability, dissolution, and packaging.
• Orange Book and Paragraph IV risk must be assessed at the individual reference-product level.
• Formulation patents can support differentiation, but narrow claims may be vulnerable to design-around strategies.
• Commercial value is highest when excipient strategy solves a recognized administration, tolerability, or consistency problem.

FAQs

Can levothyroxine be formulated without lactose?

Yes. Lactose-free levothyroxine products can use alternative fillers and binders, including cellulose-based excipients, calcium sulfate, starch systems, or liquid and softgel platforms. The replacement must maintain content uniformity, dissolution, stability, and bioequivalence.

Is Tirosint protected by a composition-of-matter patent?

No active-ingredient composition-of-matter protection remains for levothyroxine. Any relevant protection must arise from formulation, dosage form, manufacturing, packaging, method of use, or related patent claims.

Is levothyroxine oral solution more stable than tablets?

Not inherently. An oral solution can reduce tablet disintegration variability, but it creates different stability risks involving concentration uniformity, microbial control, container closure, light, temperature, and in-use handling.

Can a generic manufacturer use the same excipients as Synthroid?

A generic manufacturer may use the same or different excipients subject to FDA requirements, including safety, quality, bioequivalence, labeling, and regulatory review. It must also evaluate patent and exclusivity issues applicable to the reference product.

What excipient innovation has the highest commercial potential for levothyroxine?

The strongest opportunities are excipient-minimal oral solutions, non-gelatin softgels, lactose- and dye-free tablets, moisture-resistant packaging, and dosing systems that improve pediatric or dysphagia administration.

References

1. U.S. Food and Drug Administration. (2013). Guidance for industry: Levothyroxine sodium products: Questions and answers regarding bioequivalence. FDA.

2. AbbVie Inc. (n.d.). Synthroid prescribing information. U.S. Food and Drug Administration labeling database.

3. Alvogen, Inc. (n.d.). Levoxyl prescribing information. U.S. Food and Drug Administration labeling database.

4. IBSA Pharma Inc. (n.d.). Tirosint prescribing information. U.S. Food and Drug Administration labeling database.

5. IBSA Pharma Inc. (n.d.). Tirosint-SOL prescribing information. U.S. Food and Drug Administration labeling database.

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

7. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.